Ambrx Biopharma Management
Management criteria checks 1/4
Ambrx Biopharma’s CEO is Dan O'Connor, appointed in Nov 2022, he has a tenure of less than a year. His total yearly compensation is US$1.0m, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. He directly owns 5.0% of the company’s shares, worth US$38.5m. The average tenure of the management team and the board of directors is less than a year and less than a year respectively.
Key information
Dan O'Connor
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 6.7% |
| CEO tenure | less than a year |
| CEO ownership | 5.0% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Ambrx Biopharma (NASDAQ:AMAM) Is In A Good Position To Deliver On Growth Plans
May 25
Here's Why Ambrx Biopharma (NYSE:AMAM) Must Use Its Cash Wisely
Feb 06Ambrx Biopharma: Some Promise, Much Uncertainty
Jan 17Ambrx Biopharma receives NYSE notice for non-compliance
Dec 19Ambrx to cut workforce, pause internal development of lead cancer drug candidate
Oct 18Ambrx Biopharma GAAP EPS of -$0.19, revenue of $2.91M
Aug 29Ambrx Biopharma to offer stocks up to $300M
Jul 29CEO Compensation Analysis
| Date | Total Comp. | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$1m | US$69k | -US$78m |
Compensation vs Market: Dan's total compensation ($USD1.03M) is below average for companies of similar size in the US market ($USD3.63M).
Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.
CEO
Dan O'Connor (57 yo)
less than a year
Tenure
US$1,034,168
Compensation
Mr. Daniel J. O'Connor, J.D., also known as Dan, served as an Independent Director of ZyVersa Therapeutics, Inc. since December 13, 2022 until May 2023. He serves as President at Ambrx Biopharma Inc. since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$1.03m | 4.98% $ 38.5m | |
| Chief Financial Officer | 1.9yrs | US$1.73m | 1.81% $ 14.0m | |
| Chief Operating Officer | less than a year | no data | no data | |
| Chief Technology Officer | 1.3yrs | no data | no data | |
| Chief Scientific Officer & GM of China | less than a year | no data | no data | |
| Chief Clinical Officer | less than a year | no data | no data |
0.5yrs
Average Tenure
53yo
Average Age
Experienced Management: AMAM's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$1.03m | 4.98% $ 38.5m | |
| Independent Director | 1.3yrs | US$268.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of the Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.9yrs | US$4.13k | no data | |
| Independent Director | less than a year | US$555.41k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | US$156.12k | 0% $ 0 |
0.9yrs
Average Tenure
57.5yo
Average Age
Experienced Board: AMAM's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.